Ocular Therapeutix will restructure its operations, resulting in approximately $11 million in annualized savings, according to a press release.
The plan, which includes personnel reductions and $14 million in one-time program deferrals, will realign capital and resources to maximize commercial opportunities for Dextenza (dexamethasone ophthalmic insert 0.4 mg).
The company will also focus on completing a phase 3 trial of Dextenza for allergic conjunctivitis, a phase 1 trial of OTX-TIC for glaucoma and ocular hypertension, and a phase 1 trial of OTX-TKI for wet age-related macular degeneration,
Uncategorized